First interim toxicity analysis of the randomized phase III WSG planB trial comparing 4xC 4x Doc versus 6x T C in breast cancer patients with HER2 negative BC.

Unrike Nitz1,2, Oleg Gluz1,2, Steve Shah1, Ronald Kates1, Bernhard Liedtke1, Bahriye Aktas1,2, Stephan Henschel1, Anke Pollmanns1, Petra Krabisch1, Christoph Thomssen2, Ronald Kates1, Bernhard Liedtke4, Bahriye Aktas5, Stephan Henschen6, Anke Pollmanns7, Petra Krabisch8, Christoph Thomssen9, Hans H. Kreipe10, and Nadia Harbeck1,11 on behalf of the planB investigators

1West German Study Group, Moenchengladbach, Germany; 2Department of Obstetrics and Gynecology, Westfälische Wilhelms-Universität Münster, Münster, Germany; 3Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, USA; 4Department of Obstetrics and Gynecology, West German Study Group, Moenchengladbach, Germany; 5Breast Center, University Hospital Schleswig-Holstein, Flensburg, Germany; 6Johanniter Hospital, Stendal, Germany; 7Ev. Hospital, Oberhausen, Germany; 8Hospital Chemnitz, Chemnitz, Germany; 9Institute of Pathology, Medical College, Hanover, Germany; 10Institute of Pathology, Medical College, Hanover, Germany; 11Breast Center, Dept. OB&GYN, University Hospital of Cologne, Germany

Therapy stops

- significantly less toxicity-related therapy stops have been reported in the SAEs: 358/397, Tab. 1). There are significantly more infections (p<0.001) reported in the TC arm. Significantly more cardiovascular events were reported in older patients (>65 years) (p=0.012) treated with EC-Doc.

Dose reductions:

- disease, benefit from anthracyclines may not outweigh acute and long term therapy related deaths:
  - There were 6 therapy related deaths (TC: 5 (0.4%) / EC-Doc: 1 (0.08%); p=0.1): 5 due to sepsis, 1 due to pulmonary embolism. 3 deaths are reported in patients >65 years old (TC:Doc: 2/1 and 3 in patients >65 years old (all in the TC arm)

SUSARs:

- So far, 6 SUSARs have been reported (TC: psychosis, memory disturbance, amnesia, acute pancreatitis; EC-Doc: confusion, ataxia).

Adverse events/CTC toxicity grades:

- Data on 13,868 courses in 1,644 patients (TC: 826; EC-Doc: 818) for CTC toxicity grades are available: hematotoxicity, nausea/vomiting, mucositis, stomatitis, diarrhea, pain, skin/nail toxicity, hepatic and cardiovascular disorders, infections, and neurotoxicity. Highest CTC toxicity grades in each category per patient are evaluated.

Primary objective: disease-free survival of the two CHT arms

Secondary objectives:

- Overall survival, toxicity, evaluation of survival in patients spared from CHT, evaluation of prognostic/predictive factors

Materials & Methods

- Study design: prospective, randomized phase III study. The statistical analysis assumes n=2448 randomized to CHT (non inferiority design).
- Inclusion criteria (cht): female patients, 18-75 years
- M0 unilateral primary invasive HER2-negative BC
- pT<2, N<3, HR- / N0 / ER+ / pT<2 / N<3 / HR- / age≤75 G2/G3
- HR+ and pN0-1 and RS> 11
- Adequate organ function: albumin ≥35 G/l, platelets ≥100 G/l, hemoglobin ≥10 g/dl, total bilirubin ≤1 U/L, AST/GPT ≤2.5 ULN, creatinine ≤0.2 mg/dL, U&E and B&G within normal limits.
- Written informed consent
- Patients with HR+ and pN0-1 and RS>11 can participate (patient’s decision), but should receive endocrine treatment (ET) alone
- Main exclusion criteria: known polyneuropathy > grade 2, relevant comorbidity, prior malignancy (except basalioma of the skin, pTis cervical, after, bilateral pTis BC), time since axillary dissection >42 days, concurrent pregnancy and breast feeding

Treatment: CTC: 6 x docetaxel (75 mg/m2) + cyclophosphamide (600 mg/m2), ET and radiation is recommended according to national standard.

Primary CTC prophylaxis is recommended according to current ASCO guidelines.

Guidelines

- ET and radiotherapy according to national standards
- RS distribution in HR+ disease (n=2561): RS ≤11: 18%; RS 12-25: 60% and RS>25: 22%
- RS ≤11 - low risk: 88 % of patients (including those who withdrew consent) decided not to have CHT within the protocol. RS 12-25 - intermediate risk: 16% drop outs before randomization have been reported. Randomized to CHT. 116 drop outs in patients reported until end of treatment (6.5% of all fully documented and monitored patients, n=1783)
- 13,868 cycles of CHT have been documented so far.

Results

- From April 2009 to October 2011, 3139 patients have been recruited and 2444 (TC:1225 /EC-Doc: 1219) patients randomized (Fig. 2).
- Among the patients randomized to CHT, 1930 were <65 years old (TC/EC-Doc: 961/969) and 514 >65 years old (TC/EC-Doc: 258/256).
- Inclusion criteria (cht): female patients, 18-75 years
- M0 unilateral primary invasive HER2-negative BC
- pT<2, N<3, HR- / N0 / ER+ / pT<2 / N<3 / HR- / age≤75 G2/G3
- HR+ and pN0-1 and RS> 11
- Adequate organ function: albumin ≥35 G/l, platelets ≥100 G/l, hemoglobin ≥10 g/dl, total bilirubin ≤1 U/L, AST/GPT ≤2.5 ULN, creatinine ≤0.2 mg/dL, U&E and B&G within normal limits.
- written informed consent
- Patients with HR+ and pN0-1 and RS>11 can participate (patient’s decision), but should receive endocrine treatment (ET) alone
- Main exclusion criteria: known polyneuropathy > grade 2, relevant comorbidity, prior malignancy (except basalioma of the skin, pTis cervical, after, bilateral pTis BC), time since axillary dissection >42 days, concurrent pregnancy and breast feeding

Treatment: CTC: 6 x docetaxel (75 mg/m2) + cyclophosphamide (600 mg/m2), ET and radiation is recommended according to national standard.

Primary CTC prophylaxis is recommended according to current ASCO guidelines.

Guidelines

- ET and radiotherapy according to national standards
- RS distribution in HR+ disease (n=2561): RS ≤11: 18%; RS 12-25: 60% and RS>25: 22%
- RS ≤11 - low risk: 88 % of patients (including those who withdrew consent) decided not to have CHT within the protocol. RS 12-25 - intermediate risk: 16% drop outs before randomization have been reported. Randomized to CHT. 116 drop outs in patients reported until end of treatment (6.5% of all fully documented and monitored patients, n=1783)
- 13,868 cycles of CHT have been documented so far.

Therapy stops:

- In 1897 documented and monitored patients significantly less toxicity-related therapy stops have been reported in the TC arm (4%) compared to the EC-Doc arm (7.2%, p<0.001).
- Dose reductions: Toxicity related dose reductions occurred significantly fewer in the TC arm (5.3%) than in the EC-Doc arm (16.9%, p<0.001).
- Treatment postponement: Incidence of treatment postponement due to adverse events was significantly lower for TC (1.9% vs. 3.1% of all documented given CHT, p<0.001).
- G-CSF: Primary prophylaxis (overall 10.8%) was given significantly more frequently in the TC arm (13.6%) of all documented CHT cycles than in the EC-Doc arm (8.6%, p<0.001). Secondary prophylaxis with G-CSF was applied in 17.8% of all documented cycles and did not differ in both arms (TC: 16% vs. EC-Doc: 17.6%, n.s.).

SUSARs:

- So far, 6 SUSARs have been reported (TC: psychosis, memory disturbance, amnesia, acute pancreatitis; EC-Doc: confusion, ataxia).

Adverse events/CTC toxicity grades:

- Data on 13,868 courses in 1,644 patients (TC: 826; EC-Doc: 818) for CTC toxicity grades are available: hematotoxicity, nausea/vomiting, mucositis, stomatitis, diarrhea, pain, skin/nail toxicity, hepatic and cardiovascular disorders, infections, and neurotoxicity. Highest CTC toxicity grades in each category per patient are evaluated.

• Significantly less grade 3/4 toxicities are reported in the TC arm (n=787) vs. EC-Doc arm (n=900; p<0.001).
- Grade 3/4 toxicity is mostly restricted to hematotoxicity and infections. The difference favoring TC arm is due to lower rates of anemia, stomatitis, nausea, pain, cardiovascular disorders, vomiting, and neurotoxicity (see figure 3).

- Significantly more O3.5 infections were reported in the TC arm (6.1% vs. 3.56%, p<0.014, Fig. 3).

Summary & Discussion

- The majority (88%) of HR+/HER2- patients in planB trial with RS ≤11 opted against CHT. Higher drop out rates before CHT-randomization are reported in the intermediate risk group, RS 12-25 (16%).
- CHT administered within the study was generally well tolerated. CHT-related mortality was 6244/100.026. Clinically predominant grade 3-4 toxicities were hematotoxicity and infections followed by pain and nausea.
- Regarding more severe toxicities, TC was significantly less toxic than EC-Doc in terms of anemia, stomatitis, nausea/vomiting, pain, cardiovascular disorders, and neurotoxicity.
- These effects are even more pronounced in the population ≥65 yrs
- TC caused significantly more severe infections despite more frequent use of G-CSF in this arm.
- TC caused (non significantly) more therapy related deaths (5:1) due to infections/septicemia.
- Long term toxicity remains to be evaluated

References

4. Pink et al. JCO 2006;24(23):3728-34